Cetilistat

Selective Inhibition of Gastric and Pancreatic Lipase#

Cetilistat is a benzoxazinone-class lipase inhibitor that binds the catalytic serine residue of gastric and pancreatic lipase in the gut lumen. With lipase activity blocked, dietary triglycerides cannot be hydrolyzed into the free fatty acids and monoglycerides required for intestinal absorption — the intact triglyceride is shunted into the stool. The mechanism is functionally identical to orlistat, but the benzoxazinone scaffold appears to produce a cleaner GI tolerability profile than orlistat's β-lactone.

In vitro, cetilistat hits human pancreatic lipase with an IC₅₀ of ~5.95 nmol/L, roughly an order of magnitude more potent than against the rodent enzyme — a useful detail when interpreting preclinical-to-clinical scaling.

"Cetilistat was shown to be a novel, potent, and orally active inhibitor of pancreatic lipase that suppressed an increase in body weight and improved plasma lipid profiles in high-fat diet-induced obese rats." — Yamada Y. et al., Hormone and Metabolic Research, 2008

Quantitative Fat Malabsorption#

At the standard 120 mg t.i.d. dose, cetilistat blocks roughly 30% of ingested dietary fat from absorption — the same blockade ceiling orlistat hits at an equivalent dose. For a physique-focused user consuming 80 g of fat per day, that translates to ~215 kcal/day not crossing the intestinal barrier, which is the entire fat-loss contribution of the compound.

"Cetilistat 120 mg TID reduced dietary fat absorption by approximately 30%, comparable to orlistat at the same dose." — Bryson A. et al., British Journal of Clinical Pharmacology, 2009

This is why cetilistat is mechanistically pointless on a very-low-fat diet and mechanistically pointless on an empty stomach — without dietary triglyceride in the lumen at the same time as the drug, there is nothing for the inhibited lipase to fail at.

No Systemic Absorption, No Central Effect#

Cetilistat is gut-localized by design. Systemic bioavailability is negligible; the drug is recovered largely unchanged in feces alongside the triglyceride load it bound. There is no central appetite suppression, no GLP-1 or leptin axis involvement, no sympathomimetic activity, and no HPTA interaction. This is why the compound stacks cleanly with essentially every fat-loss agent in the community toolkit — GLP-1/GIP agonists, clenbuterol, yohimbine, T3, metformin — and why it requires no PCT and applies equally across the full subject pool.

The practical translation: cetilistat does not touch hunger, cravings, satiety, or energy expenditure. It is a digestive-absorption block, not a metabolic accelerator. Protocols that confuse it for an appetite suppressant underperform every time.

Indirect Lipid Profile Improvement#

Because absorbed dietary fat is reduced — including saturated fat — postprandial chylomicron formation drops, which in turn lowers the absorbed lipid load reaching the liver. The Phase II data showed 3–11% reductions in total and LDL cholesterol across all studied doses, independent of the weight-loss effect.

"After 12 weeks, the mean weight loss in the 120 mg t.i.d. cetilistat group was 3.5 kg, which was statistically significantly greater than with placebo (1.9 kg). All active groups showed improvements in lipid parameters." — Kopelman P. et al., International Journal of Obesity, 2007

For the lifter running oral AAS, this is the secondary mechanism worth knowing about: layered onto a broader lipid-management strategy (omega-3, citrus bergamot, cardio), it provides one additional indirect lever on the LDL/HDL ratio that orals dose-dependently degrade.

Fat-Soluble Vitamin and Lipophilic Drug Interaction#

The same mechanism that blocks dietary triglyceride absorption also blocks the absorption of anything that piggybacks on the fat-absorption pathway: vitamins A, D, E, K, carotenoids, and lipophilic orals (cyclosporine, levothyroxine, oral AAS, isotretinoin). This is not a side effect — it is the mechanism applied to molecules other than triglyceride.

The protocol consequence is straightforward: fat-soluble vitamin supplementation is dosed ≥2 hours away from cetilistat, and lipophilic orals are separated by ≥3–4 hours. 25-OH vitamin D is the most commonly depleted marker on extended protocols and is the one worth tracking on bloodwork at 8–12 week intervals.

Tolerability Advantage Over Orlistat#

Head-to-head trial data put cetilistat and orlistat at functionally identical efficacy with materially fewer GI-driven dropouts on cetilistat — the practical reason the compound has a niche at all.

"Cetilistat 80 and 120 mg TID produced significant reductions in body weight (−3.85 kg and −4.32 kg, respectively) and HbA1c, with fewer GI adverse events compared to orlistat." — Kopelman P. et al., Obesity, 2010

The mechanistic interpretation: the benzoxazinone binds lipase reversibly and is less prone to producing the free-oil pooling in the colon that drives orlistat's signature steatorrhea and oily incontinence events. Same lipase blockade, gentler downstream stool consequences — which is why orlistat-intolerant users typically migrate to cetilistat at the same 120 mg t.i.d. schedule and stay there.

Common (most users)#

The side-effect profile of cetilistat is almost entirely gastrointestinal and dose-coupled to dietary fat intake — the more fat consumed at a given meal, the more pronounced the local GI effect. None of these are systemic; all resolve on discontinuation or dose adjustment.

• Oily or loose stools — the signature effect. Reported in roughly 1.8–2.8% of subjects at 120 mg t.i.d. in the Kopelman 2007 dataset, materially lower than the orlistat comparator arm. Mitigated by keeping per-meal dietary fat under ~30 g; cap any single meal that is paired with a dose.
• Oily spotting / soft stools — typically appears within the first week and attenuates as the gut adapts. Reducing the dose to 60–80 mg per meal during the adaptation window is the standard adjustment.
• Flatus with discharge — disproportionately triggered by single very-high-fat meals (pizza, fried food, heavy cream sauces). The community fix is meal composition, not premedication.
• Fecal urgency, increased bowel-movement frequency — usually a one-to-two-week adaptation phenomenon at 120 mg t.i.d. Stable thereafter.
• Reduced absorption of fat-soluble vitamins (A, D, E, K) and carotenoids — a real, predictable effect on extended protocols. A standard fat-soluble multivitamin dosed ≥2 hours away from cetilistat offsets it.

"Cetilistat appears to produce weight loss and metabolic benefit comparable to orlistat, but with better gastrointestinal tolerability." — Padwal, Current Opinion in Investigational Drugs (2008)

Uncommon (dose-dependent or individual)#

• Steatorrhea on very-high-fat meals — frank fatty stool, distinct from oily spotting. Indicates the meal's fat load exceeded what the protocol can manage cleanly. Reduce per-meal fat or drop that meal's dose to 60 mg.
• 240 mg per-meal GI ceiling — the 240 mg t.i.d. arm in the Kopelman 2007 trial added only marginal weight loss (~0.6 kg over 12 weeks vs the 120 mg arm) while disproportionately increasing GI events. The literature does not support exceeding 120 mg per meal.
• 25-OH vitamin D depletion — the most commonly affected fat-soluble vitamin on extended protocols (>12 weeks), compounded by the indoor-training population already running low at baseline. Check at baseline and at 8–12 weeks; supplement at least 2 hours away from any cetilistat dose.
• Altered INR on warfarin therapy — reduced vitamin K absorption can shift coagulation parameters. Frequent INR monitoring is required if both are run concurrently.
• Reduced absorption of co-administered lipophilic compounds — oral AAS, isotretinoin, levothyroxine, cyclosporine, and other lipid-soluble orals all show or are expected to show reduced absorption when dosed near cetilistat. Separate by ≥3–4 hours.

Rare but serious#

• Hepatotoxicity — a small number of post-marketing case reports exist for cetilistat-associated liver injury, paralleling the rare orlistat hepatic signal. The clinical-trial database did not show meaningful LFT derangement, but baseline and 8–12 week ALT/AST checks are prudent on extended protocols. Discontinue on persistent RUQ pain, jaundice, dark urine, or ALT/AST elevations >3× ULN.
• Oxalate nephropathy — a class-effect concern with GI lipase inhibitors (unabsorbed fatty acids bind calcium in the gut, leaving free oxalate to be absorbed and excreted). Documented more clearly with orlistat than cetilistat, but mechanistically applicable. Subjects with a history of calcium-oxalate stones should avoid the protocol.
• Cholelithiasis — any rapid-weight-loss intervention raises gallstone risk; cetilistat-driven loss is modest enough that this is a minor concern, but RUQ pain warrants imaging.

Hard contraindications#

• Chronic malabsorption syndromes — Crohn's, celiac, cholestasis, short-bowel — do not layer a lipase inhibitor on top of pre-existing fat malabsorption.
• Cyclosporine therapy — significant reduction in cyclosporine absorption is documented for orlistat and expected as a class effect. Avoid.
• Warfarin therapy without active INR monitoring — vitamin K absorption is reduced; INR will shift.
• Pregnancy — fat-soluble vitamin (A, D, K) malabsorption raises teratogenicity-adjacent concerns. Not used.
• Very-low-fat diets (<30 g/day) — not dangerous, but pharmacologically pointless; the absolute calories blocked are trivial.

Gender, PCT, and population notes#

Cetilistat has no hormonal activity — no estrogenic, androgenic, progestogenic, or HPTA effect. The mechanism is fully gut-localized, with negligible systemic exposure. No PCT is required, and the protocol is equally applicable across the full subject pool — the Kopelman and Kawai trials enrolled both male and female subjects with no gender-specific tolerability signal. The single population-level caution outside the contraindications above is pregnancy, where fat-soluble vitamin depletion is the limiting factor rather than any direct compound effect.

"Cetilistat 80 and 120 mg TID produced significant reductions in body weight (−3.85 kg and −4.32 kg, respectively) and HbA1c, with fewer GI adverse events compared to orlistat." — Kawai et al., Obesity (2010)

Used within the dose ceiling, paired with reasonable per-meal fat caps, and supported by a fat-soluble vitamin layer dosed away from administration, the protocol is one of the cleaner adjuncts available in the metabolic toolkit — well-characterized side effects, all mitigable, none that compromise the rest of a cycle.